Osteopenia, Osteoporosis Clinical Trial
— SENIOROfficial title:
SENolytics to Improve Osteoporosis Therapy: a Randomised Controlled Clinical Trial The SENIOR Trial
This randomised clinical trial aims to study osteoporosis as a disease of accelerated skeletal aging caused by the accumulation of senescent cells within the skeleton and investigate the effects and safety of senolytics and antioxidant therapy on bone.
Status | Recruiting |
Enrollment | 120 |
Est. completion date | December 31, 2025 |
Est. primary completion date | December 31, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 60 Years to 90 Years |
Eligibility | Inclusion Criteria: - Men and women (menopause > 5 years and FSH and LH in the postmenopausal range) aged 60-90 years with increased fracture risk according to WHO 10 years absolute Fracture Risk Assessment Tool (FRAX) 1. osteopenia (ICD10 DM858A) based on a T-score = -2 to -2.5 at the total hip/femoral neck, or lumbar spine (FRAX score ranging from 10-70) 2. osteopenia (ICD10 DM858A) based on a T-score < -1 to -2.5 and a fragility fracture at any time (excluding hip and vertebral fractures within the last 2 years) (FRAX ranging from 11-68) 3. osteoporosis (ICD10 DM819) based on a T-score between >-3 and = -2.5, which includes candidates suitable for conventional osteoporosis therapies, but who prefer to participate in the trial, despite being candidates for conventional osteoporosis therapy, or candidates which cannot be treated with conventional therapies due to contraindications. - Ability to provide informed consent Exclusion Criteria: - DXA of hip or spine not possible e.g., due to a prosthesis - Inability to provide fasting blood samples - Primary hyperparathyroidism - Vitamin D deficiency (<50 nM) (re-test after substitution acceptable) - Known disorders affecting bone metabolism, e.g., uncontrolled thyrotoxicosis, chronic kidney disease defined as eGFR <30 or liver dysfunction, rheumatism, celiac disease/malabsorption, hypogonadism, severe COPD, hypopituitarism, Cushing's disease, uncontrolled diabetes (HbA1c > 58 mmol/mol). - Antiresorptive or bone anabolic drugs for the last 2 years (5 years if treated with zoledronic acid) - Concomitant treatments known to influence bone metabolism e.g., glucocorticoids (systemic treatments), anabolic steroids, etc. - Subjects taking the following other drugs if they cannot be held for at least 2 days before and during administration of D+Q: digoxin, lithium, all statins, repaglidine, bosentan, gemfibrozil, olmesartan, enalapril, valsartan, methotrexate, corticosteroids, eluxadoline, eltrombopag, nitroglycerin, pioglitazone, glyburide, enzalutamide, ezetimibe, colchicine, imatinib, cyclosporine, tacrolimus, sirolimus, carbamazepine, flecainide, phenytoin, phenobarbital, rifampicin, theophylline, warfarin, heparin, clopidogrel, celecoxib, desipramine, thioridazine, venlafaxine, tizanidine, atomoxetine, voriconazole, citalopram, diazepam, escitalopram, propranolol, clozapine, cyclobenzaprine, mexiletine, olanzapine, ondansetron - Subjects taking medications that are sensitive to substrates or substrates with a narrow therapeutic range for CYP3A4, CYP2C8, CYP2C9, or CYP2D6 or strong inhibitors or inducers of CYP3A4 (e.g., cyclosporine, tacrolimus or sirolimus). If antifungals are necessary from an infectious disease perspective, then they will be allowed only if the levels are therapeutic. - Subjects taking proton pump inhibitors and unwilling to discontinue therapy for two days before and during the study drug dosing periods. - Anti-arrhythmic medications known to cause QTc prolongation - Tyrosine kinase inhibitor therapy - Subjects with an abnormal Complete Blood Count (clinically insignificant changes would be acceptable based on the judgement of the investigators) - Subjects on antiplatelet agents (Clopidogrel; Dipyridamole + ASA; ASA, Ticagrelor; Prasugrel; Ticlopidine or other) who are unable or unwilling to reduce or hold therapy prior to and during the study drug dosing periods and collection of bone biopsies. Subjects may continue their previous regimen between study drug dosing periods. - Known allergy to dasatinib, quercetin, or nicotinamide riboside - Subjects taking the following antimicrobial agents: Aminoglycosides, Azole antifungals (fluconazole, miconazole, voriconazole, itraconazole), Macrolides (clarithromycin, erythromycin), antivirals (nelfinavir, indinavir, saquinavir, ritonavir, elbasvir/grazoprevir) - Presence of any condition the Investigator believes would place the subject at risk or would preclude the subject from successfully completing all aspects of the trial e.g., heart failure, malignancy etc. - QTc >470 msec - Inability to take oral medication - The study will exclude subjects with inability to speak and understand Danish and with inability to cooperate |
Country | Name | City | State |
---|---|---|---|
Denmark | Odense University Hospital | Odense |
Lead Sponsor | Collaborator |
---|---|
Odense University Hospital | Novo Nordisk A/S, Odense Patient Data Explorative Network |
Denmark,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Bone resorption marker CTX | Change in circulating marker of bone resorption C-terminal telopeptide of type I collagen (CTX) at 21 weeks. | Baseline, week 5, week 13, week 21 | |
Secondary | Bone resorption marker TRAcP | Change in circulating marker of bone resorption Tartrate Resistant Acid Phosphatase (TRAcP) at 21 weeks. | Baseline, week 5, week 13, week 21 | |
Secondary | Bone formation markers (PINP, osteocalcin, and bone alkaline phosphatase) | Change in circulating markers of bone formation (PINP, osteocalcin, and bone alkaline phosphatase) at 21 weeks. | Baseline, week 5, week 13, week 21 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04122638 -
Prevalence of Sarcopenia and Sarcopenic Obesity in Older Adults
|
||
Completed |
NCT03709381 -
Effect of Adrenocorticotropic Hormone on Vascular Endothelial Growth Factor Release in Children Study
|
Early Phase 1 | |
Completed |
NCT03819478 -
Utilizing Protein During Weight Loss to Impact Physical Function and Bone
|
N/A | |
Recruiting |
NCT01857154 -
A Study of Changes in Bone Mineral Density as a Function of Consuming Two Different Forms of Calcium Carbonate
|
N/A | |
Not yet recruiting |
NCT04719572 -
Intervention Study of Drugs in Patients Osteopenia and Osteoporosis
|
N/A | |
Active, not recruiting |
NCT04708886 -
Romosozumab in Women With Chronic SCI
|
Phase 2 | |
Completed |
NCT03959995 -
Effects of Physical Exercise on Postmenopausal Risk Factors in Women With Osteopenia
|
N/A |